Neurological involvement in patients with rheumatic disease

QJM: An International Journal of Medicine

Volumn 99, Issue 2, 2006, Pages 69-79

  Sofat, N ^a   Malik, O ^b   Higgens, C S ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VALPROIC ACID; VITAMIN D; WARFARIN;

ANGIOPLASTY; ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; AORTA ARCH SYNDROME; BEHAVIOR MODIFICATION; BEHCET DISEASE; CERVICAL SPINE DISLOCATION; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEMYELINATING DISEASE; DERMATOMYOSITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; EARLY DIAGNOSIS; GIANT CELL ARTERITIS; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYME DISEASE; MIXED CONNECTIVE TISSUE DISEASE; MORBIDITY; MYOSITIS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET BONE DISEASE; PATIENT MONITORING; PERIPHERAL NERVE INJURY; POLYARTERITIS NODOSA; POLYMYOSITIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SJOEGREN SYNDROME; SPINAL CORD COMPRESSION; SURGICAL TECHNIQUE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; TEMPORAL ARTERITIS; TREATMENT FAILURE; WEGENER GRANULOMATOSIS;

EID: 32244432869     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl005     Document Type: Review

References (100)

1. Muhammed N, Campbell P, Smith IS. Peripheral nerve entrapment syndromes: diagnosis and management. Br J Hosp Med 1995; 53:141-6.
2. Olsen ML, O'Connor S, Arnett FC, Rosenbaum D, Grotta JC, Warner NB. Autoantibodies and rheumatic disorders in a neurology inpatient population: A prospective study. Am J Med 1991; 90:479-88.
3. Sellar RJ. Imaging blood vessels of the head and neck. J Neurol Neurosurg Psychiatry 1995; 59:225-37.
4. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998; 29:2245-53.
5. Brey RL, Gharavi AE, Lockshin MD. Neurologic complications of antiphospholipid antibodies. Rheum Dis Clin North Am 1993; 19:833-50.
6. Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99:397-401.
7. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90:54-62.
8. Teh L-S, Isenberg DA. Antiribosomal P antibodies in systemic lupus erythematosus: A reappraisal. Arthritis Rheum 1994; 37:307-15.
9. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Bollart L, Serre G, Veys EM, De Keyser F. Rheumatoid factor and anticitrullinated antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
10. Said G. Vasculitic neuropathy. Curr Opin Neurol 1999; 12:627-9.
11. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific antibodies: Changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16:692-9.
12. Kim RC, Collins GH. The neuropathology of rheumatoid disease. Hum Pathol 1981; 12:5-15.
13. Cupps TR, Fauci AS. The vasculitic syndromes. Adv Intern Med 1982; 27:144-315.
14. Bekkelund SI, Mellgren SI, Proven A, Husby G. Quantified neurological examination with emphasis on motor and sensory functions in patients with rheumatoid arthritis and controls. Br J Rheumatol 1996; 35:1116-21.
15. Tsegaye M, Bassi S, Ashpole RD. Extradural spinal cord compression by rheumatoid nodule. Br J Neurosurg 2003; 17:255-7.
16. Fairburn B. Spinal cord compression by a rheumatoid nodule. J Neurol Neurosurg Psychiatry 1975; 38:1056-8.
17. Arroyo IL, Barron KS, Brewer EJ Jr. Spinal cord compression by epidural lipomatosis in juvenile rheumatoid arthritis. Arthr Rheum 1988; 31:447-5.
18. Castro S, Verstraete K, Mielants H, Vanderstraeten G, de Reuck J, Veys EM. Cervical spine involvement in RA: A clinical, neurological and radiological evaluation. Clin Exp Rheumatol 1994; 12:369-74.
19. Agildere AM, Tutar NU, Yucel E, Coskum M, Benli S, Aydin P. Pachymeningitis and optic neuritis in rheumatoid arthritis: MRI findings. Br J Radiol 1999; 72:404-7.
20. Neva MH, Isomaki P, Hannonen P, Kauppi M, Krishnan E, Sokka T. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:1808-13.
21. Hermann KG, Bollow M. Magnetic resonance imaging of the axial skeleton in rheumatoid disease. Best Prac Res Clin Rheumatol 2004; 18:881-907.
22. Kinnunen E, Kauppi M, Ketonen L, Sepponen R, Tanttu J, Konttinen YT, Isomaki H. Low-field MRI in evaluation of rheumatoid cervical spine: comparison with neurological findings and routine plain radiography. Clin Exp Rheumatol 1990; 8:365-9.
23. Louthrenoo W, Zager EL, Freundlich B, Zurier RB. Intravenous corticosteroid therapy of cervical cord compression in rheumatoid arthritis. Clin Exp Rheumatol 1992; 10:173-5.
24. Stanley D, Laing RJ, Forster DM, Getty CJ. Posterior decompression and fusion in rheumatoid disease of the cervical spine: Redressing the balance. J Spinal Disord 1994; 7:439-43.
25. Casey AT, Crockard HA, Bland JM, Stevens J, Moskovich R, Ransford AO. Surgery on the rheumatoid cervical spine for the non-ambulant myelopathic patient - too much, too late? Lancet 1996; 347:1004-7.
26. Singh A, Crockard HA. Quantitative assessment of cervical spondylotic myelopathy by a simple walking test. Lancet 1999; 354:370-3.
27. Sivri A, Guler-Uysal F. The electroneurophysiological findings in RA patients. Electromyogr Clin Neurophysiol 1999; 39:387-91.
28. Katz JN, Simmons BP. Clinical Practice. Carpal tunnel syndrome. N Engl J Med 2002; 346:1807-12.
29. Marshall S. Carpal tunnel syndrome. Clinical Evidence Concise 2003; 10:244-6. (Full version: [http://www.nelh.nhs.uk/clinicalevidence]).
30. The ACR nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599-608.
31. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum and relationship to other features of the disease. Medicine 1976; 55:323-39.
32. Loukkola J, Laine M, Ainiala H, Peltola J, Metsanoja R, Auvinen A, Hietaharju A. Cognitive impairment in SLE and neuropsychiatric SLE: A population-based neuropsychological study. J Clin Exp Neuropsychol 2003; 25:145-51.
33. McNicholl JM, Glynn D, Mongey AB, Hutchinson M, Bresnihan B. A prospective study of neurophysiologic, neurologic and immunologic abnormalities in SLE. J Rheumatol 1994; 21:1061-6.
34. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in SLE: An analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59:120-4.
35. Appenzeller S, Cendes F, Costellat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63:1808-12.
36. Brey RL, Holliday SL, Saklad AR, Navarette MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del Rincon I, Gronseth G, Rhine CB, Padilla P, McGlasson D. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58:1214-20.
37. Brey RL, Sakic B, Szechtman H, Denburg JA. Animal models for nervous system disease in SLE. Ann N Y Acad Sci 1997; 823:97-106.
38. McLean BN. Neurological involvement in SLE. Curr Opin Neurol 1998; 11:247-51.
39. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: A 10 year prospective study on the value of diagnostic tests. Am J Med 1995; 99:153-63.
40. Carr RI, Harbeck RJ, Hoffman AA, Pirofsky B, Bardana EJ. Clinical studies on the significance of DNA: Anti-DNA complexes in the systemic circulation and cerebrospinal fluid (CSF) of patients with SLE. J Rheumatol 1975; 2:184-93.
41. Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 2004; 46:15-21.
42. Govoni M, Castellino G, Padovan M, Borrelli M, Trotta F. Recent advances and future perspective in neuroimaging in neuropsychiatric SLE. Lupus 2004; 13:149-58.
43. Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, Otto P, Nitzsche EU, Moser E, Peter HH. PET scanning with F-18-labelled fluorodeoxyglucose in 28 SLE patients. Ann Rheum Dis 2000; 59:377-85.
44. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric SLE (NPSLE). Best Prac Res Clin Rheumatol 2002; 16:229-44.
45. McLean BN. Neurological involvement in systemic lupus erythematosus. Curr Opin Neurol 1998; 11:247-51.
46. Lampropoulos CE, Koutroumanidis M, Reynolds PP, Manidakis I, Hughes GR, D'Cruz DP. Electroencephalography in the assessment of neuropsychiatric manifestions in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum 2005; 52:841-6.
47. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: A clinical approach to therapy. Lupus 2003; 12:935-42.
48. Jennette JC, Falk R, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides: Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-92.
49. Lightfoot RW, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088-93.
50. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg Strauss syndrome: Clinical aspects and treatment. Rheum Dis Clin North Am 1995; 21:911-47.
51. Urich H. Observations on vascular neuropathies. Clin Exp Neurol 1977; 14:162-71.
52. Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol 1983; 14:155-67.
53. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu's arteritis. Arthritis Rheum 1990; 33:1129-34.
54. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS. Takayasu's arteritis. Ann Intern Med 1994; 120:919-29.
55. Andrews J, Al-Nahhas A, Pennell DJ, Hossain MS, Davies KA, Haskard DO, Mason JC. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis 2004; 63:995-1000.
56. Hunder GG, Bloch DA, Michel BA, Stvens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RJ, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33:1122-8.
57. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis, a 25-year epidemiologic, clinical and pathological study. Ann Intern Med 1978; 88:162-7.
58. Reich KA, Giansiracusa DF, Strongwater SL. Neurologic manifestations of giant cell arteritis. Am J Med 1990; 89:67-72.
59. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005; 17:9-15.
60. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener's granulomatosis: An analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33:4-9.
61. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101-7.
62. Lightfoot RW, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, Arend WP, Calabrese LH, Leavitt RY, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088-93.
63. Walker GL. Neurological features of polyarteritis nodosa. Clin Exp Neurol 1978; 15:237-47.
64. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094-100.
65. Lhote F, Guillevein L. Polyarteritis nodosa, microscopic polyangiitis and Churg Strauss syndrome: Clinical aspects and treatment. Rheum Dis Clin North Am 1995; 21:911-48.
66. Solans R, Bosch JA, Perez-Bocanegra C, Selva A, Huguet P, Alijotas J, Orriols R, Armadans L, Vilardell M. Churg-Strauss syndrome: Outcome and long-term follow-up of patients. Rheumatology (Oxford) 2001; 40:763-71.
67. International Study Group for Behcet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335:1078-80.
68. Siva A, Altintas A, Saip S. Behçet's syndrome and the nervous system. Curr Opin Neurol 2004; 17:347-57.
69. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain 1999; 122:2183-94.
70. Palacio E, Rodero L, Pacual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Behcet syndrome. Headache 2004; 44:436-7.
71. Govoni M, Padovan M, Rizzo N, Trotta F. CNS involvement in primary Sjögren's syndrome: Prevalence, clinical aspects, diagnostic assessment and therapeutic approaches. CNS Drugs 2001; 15:597-607.
72. Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, van Meiracker AH, Vecht CJ, van der Heijde GL, Markusse HM. Involvement of the peripheral nervous sytem in primary Sjogren's syndrome. Ann Rheum Dis 2001; 60:876-81.
73. Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Slachas F, Leger JM, Piette JC, Delattre JY. Neurological complications of primary Sjogren's syndrome. J Neurol 2001; 248:577-84.
74. Mochizuki H, Kamakura K, Masaki T, Hirata A, Nakamura R, Motoyoshi K. Motor dominant neuropathy in Sjogren's syndrome: A report of two cases. Intern Med 2002; 41:142-6.
75. Yamada S, Mori K, Matsuo K, Inukai A, Kawashigura Y, Sobue G. Interferon alfa treatment for Sjogren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 2005; 76:576-8.
76. Hilton-Jones D. Inflammatory muscle diseases. Curr Opin Neurol 2001; 14:591-6.
77. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991; 325:1487-98.
78. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheumatology (Oxford) 2002; 41:22-6.
79. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291:2367-75.
80. Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol 2003; 50:10-15.
81. Stone J, Franks AJ, Guthrie JA, Johnson MH. Scleroderma 'en coup de sabre': Pathological evidence of intracerebral inflammation. J Neurol Neurosurg Psychiatry 2001; 70:382-5.
82. Gambichler T, Kreuter A, Hoffman K, Bechara FG, Altmeyer P, Jansen T. Bilateral linear scleroderma 'en coup de sabre' associated with facial atrophy and neurological complications. BMC Dermatol 2001; 1:9.
83. Allanore Y, Zuber M, Kahan A. Brachial plexopathy associated with systemic sclerosis. Clin Rheumatol 2002; 21:401-2.
84. Grosso S, Fioravanti A, Biasi G, Conversano E, Marcolongo R, Morgese G, Balestri P. Linear scleroderma associated with progressive brain atrophy. Brain Dev 2003; 25:57-61.
85. Nadeau SE. Neurological manifestations of connective tissue disease. Neurol Clin 2002; 20:151-78.
86. Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis and malignant conditions: Our experience with 200 patients. J Clin Immunol 2004; 24:107-14.
87. Nowak DA, Widenka DC. Neurosarcoidosis: A review of its intracranial manifestation. J Neurol 2001; 248: 363-72.
88. Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol 2004; 17:311-16.
89. Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B, Bither MO, Bletry O, Laplane D, Bonsser MG, et al. Neurosarcoidosis: Signs, course and treatment in 35 confirmed cases. Medicine 1990; 69:261-76.
90. Roberts SD, Wilkes SD, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124:2028-31.
91. Fox MW, Onofrio BM, Kilgore JE. Neurological complications of ankylosing spondylitis. J Neurosurg 1993; 78:871-8.
92. Ramos-Remus C, Gomez-Vargas A, Guzman-Guzman JL, Jimenez-Gil F, Gamez-Nava JI, Gonzalez-Lopez L, Farrera-Gamboa H, Maksymowych WP, Suarez-Almazor ME. Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. J Rheumatol 1995; 22:2120-5.
93. National Osteoporosis Society. PDF file on glucocortocoids and osteoporosis. [http://www.nos.org.uk].
94. British National Formulary. DK Mehta, ed. September 2004.
95. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. London, NICE, 2002. [http://www.nice.org.uk].
96. Uthman I. Pharmacological therapy of vasculitis: An update. Curr Opin Pharmacol 2004; 4:177-82.
97. Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5:25-35.
98. Sfikakis PP. Behçet's disease: A new target for anti-tumour necrosis factoI treatment. Ann Rheum Dis 2002; 61:(Suppl. 2):ii 51-3.
99. Khanna D, McMahon M, Furst DE. Safety of tumor necrosis factor-alpha antagonists. Drug Saf 2004; 27:307-24.
100. Scheinfeld N. A comprehensive review and evaluation of the side effects of tumor necrosis alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15:280-94.